研究等業績 - その他 - 成田　伸太郎

[Pazopanib for three patients with recurrence of retroperitoneal liposarcoma : initial clinical experience].

Atsushi Koizumi, Takamitsu Inoue, Koichiro Takayama, Makoto Takahashi, Kazuyuki Numakura, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Shintaro Narita, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi

Hinyokika kiyo. Acta urologica Japonica   61 ( 4 ) 153 - 8   2015年04月

Pazopanib, a novel tyrosine kinase inhibitor, is an effective therapeutic agent for patients with advanced soft tissue sarcoma. Here we report three patients with recurrent retroperitoneal liposarcoma who were treated with pazopanib. Case 1: A 54-year-old male received three courses of combined chemotherapy consisting of doxorubicin and ifosfamide for recurrent left retroperitoneal dedifferentiated liposarcoma and liver metastasis following tumor excision. Because of the lack of response to chemotherapy, 400 mg/day of pazopanib was subsequently administered for two weeks. The patient died 3 weeks after the initiation of pazopznib therapy. Case 2: A 78-year-old male with right retroperitoneal dedifferentiated liposarcoma underwent irradiation for a recurrent tumor 16 months after the initial tumor excision. Pazopanib (600 mg/day) was partially effective for 2 months. Pazopanib was administered for 7 months, but the patient died 8 months after the initiation of pazopanib therapy. Case 3 : An 80-year-old male with locally recurrent right retroperitoneal myxoid liposacroma was treated with 600 mg/day of pazopanib from 5 months after tumor excision. He remains alive and has had stable disease for 17 months to date. In conclusion, pazopanib may be effective in a subset of patients with recurrent retroperitoneal liposarcoma.

PubMed

A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.

Takuya Koie, Koji Mitsuzuka, Shintaro Narita, Takahiro Yoneyama, Sadafumi Kawamura, Yasuhiro Kaiho, Norihiko Tsuchiya, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama

Scandinavian journal of urology   49 ( 2 ) 103 - 7   2015年04月

OBJECTIVE: Prostate cancer (PCa) may be a multifocal and bilateral disease. Patients with low-risk PCa and a low number of positive biopsy cores may choose to undergo active surveillance or focal therapy. The aim of this study was to determine the correlation between a solitary positive prostate biopsy core and the pathological outcome after radical prostatectomy (RP). MATERIAL AND METHODS: The Michinoku Japan Urological Cancer Study Group database contains data, including preoperative and postoperative information, on 1268 consecutive patients with PCa treated with RP alone at four institutions. This study focused on 151 patients with a single positive biopsy core, preoperative prostate-specific antigen (PSA) level less than 10 ng/ml, biopsy Gleason score less than 8, and clinical stage T1c/T2a/T2b disease. Potential preoperative predictors of unilateral PCa were age, preoperative PSA level, biopsy Gleason score and clinical T stage. RESULTS: The median age and preoperative PSA level were 65 years (range 47-76 years) and 6.00 ng/ml (range 0.50-9.80 ng/ml), respectively. Unilateral PCa was identified in 41% of the patients. Extraprostatic extension or seminal vesicle invasion was observed in 26% of all patients. CONCLUSION: Serum PSA levels were significantly higher in the bilateral PCa group than in the unilateral PCa group in the current study. For patients with PCa having a solitary positive prostate biopsy core, definitive therapy such as RP should be considered.

DOI PubMed

Successful introduction of laparoendoscopic single-site donor nephrectomy after experience with laparoscopic single-site plus-one trocar donor nephrectomy.

Takamitsu Inoue, Norihiko Tsuchiya, Shintaro Narita, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Shigeru Satoh, Tomonori Habuchi

Journal of endourology   29 ( 4 ) 435 - 42   2015年04月

PURPOSE: To assess the feasibility, safety, and efficacy of the laparoendoscopic single-site (LESS) donor nephrectomy (LESSDN) procedure after experience with the LESS-plus-one-trocar donor nephrectomy (LEPODN) procedure. PATIENTS AND METHODS: From 2009 to 2014, 126 left laparoscopic donor nephrectomies (LDNs) were performed, including 59 Standard (Std)-LDN, 30 LEPODN, and 37 LESSDN. In the LEPODN procedure, a 5-mm trocar was added as a right-hand working trocar to the LESSDN procedure. A GelPOINT(®) platform was applied on a pararectal single incision in both LEPODN and LESSDN procedures. After performing the LEPODN procedure several times, each surgeon performed the LESSDN procedure. RESULTS: Std-LDN, LEPODN, and LESSDN procedures were performed by 10, 10, and 7 surgeons, respectively. The mean operative time, estimated blood loss, warm ischemia time, time to ambulation, and length of postoperative hospital stay were the shortest for the LESSDN procedure (P<0.012, P=0.007, P<0.001, P=0.027, and P=0.001, respectively). No significant difference in the complication rate, delayed graft function rate, and mean 7-day post-transplant serum creatinine levels was observed among the three procedures. Individual results of the operative time and estimated blood loss for the LESSDN procedure were not significantly inferior to those of Std-LDN and LEPODN procedures for each surgeon. CONCLUSIONS: The LESSDN procedure can be introduced safely and effectively without compromising the operative time, complication rate, and graft function after experience with the LEPODN procedure among multiple surgeons. The LEPODN procedure may be an effective bridge from standard multiport LDN to LESSDN.

DOI PubMed

ASSOCIATION BETWEEN PLASMA CONCENTRATION OF AXITINIB AND TREATMENT OUTCOME IN ADVANCED RENAL CELL CARCINOMA PATIENTS

Norihiko Tsuchiya, Nobuhiro Fujiyama, Ryoma Igarashi, Naoko Honma, Shintaro Narita, Takamitsu Inoue, Kazuyuki Numakura, Susumu Akihama, Mitsuru Saito, Shigeru Satoh, Masatomo Miura, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E872 - E873   2015年04月

研究発表要旨（国際会議）  

CASTRATION-INDUCED ACCELERATION OF BONE METASTASIS PREVENTED BY RANK INHIBITOR OSTEOPROTEGERIN IN MURINE CASTRATION-RESISTANT PROSTATE CANCER MODEL

Koichiro Takayama, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Yoko Mitobe, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Norihiko Tsuchiya, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E549 - E550   2015年04月

研究発表要旨（国際会議）  

CLINICAL OUTCOME OF SINGLE NUCLEOTIDE POLYMORPHISMS ON PHARMACOKINETIC GENES IN JAPANESE METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH SUNITINIB

Kazuyuki Numakura, Norihiko Tsuchiya, Makoto Takahashi, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Tkamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E867 - E867   2015年04月

研究発表要旨（国際会議）  

DYSLIPIDEMIA IN THE FIRST YEAR AFTER KIDNEY TRANSPLANTATION: INCIDENCE, CLINICAL CHARACTERISTICS, PHARMACOKINETICS OF IMMUNOSUPPRESSIVE DRUGS, AND RELATED GENOMIC POLYMORPHISMS

Kazuyuki Numakura, Shigeru Satoh, Norihiko Tsuchiya, Komine Naoki, Mitsuru Saito, Tkamitsu Inoue, Shintaro Narita, Hideaki Kagaya, Masatomo Miura, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E1071 - E1071   2015年04月

研究発表要旨（国際会議）  

EFFECT OF OBESITY AND ADIPONECTIN SIGNALING IN PATIENTS WITH RENAL CELL CARCINOMA TREATED WITH SURGERY

Ryuichi Itoh, Shintaro Narita, Mingguo Huang, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Takamitsu Inoue, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E457 - E458   2015年04月

研究発表要旨（国際会議）  

EXPRESSION OF ANDROGEN AND GLUCOCORTICOID RECEPTORS IN RESIDUAL CANCER CELLS AFTER NEOADJUVANT CHEMOHORMONAL THERAPY WITH DOCETAXEL FOR HIGH-RISK LOCALIZED PROSTATE CANCER

Shintaro Narita, Taketoshi Nara, Mingguo Huang, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Takamitsu Inoue, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E1053 - E1053   2015年04月

研究発表要旨（国際会議）  

INVERSE RELATIONSHIP BETWEEN INSULIN RECEPTOR EXPRESSION AND CANCER PROGRESSION IN RENAL CELL CARCINOMA: CLINICAL AND EXPERIMENTAL EVALUATION

Makoto Takahashi, Takamitsu Inoue, Mingguo Huang, Hiroshi Tsuruta, Mitsuru Saito, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E710 - E711   2015年04月

研究発表要旨（国際会議）  

LYMPHOVASCULAR INVASION IS SIGNIFICANTLY ASSOCIATED WITH BIOCHEMICAL RELAPSE AFTER RADICAL PROSTATECTOMY EVEN IN PATIENTS WITH PT2N0 NEGATIVE RESECTION MARGIN

Koji Mitsuzuka, Shintaro Narita, Takuya Koie, Yasuhiro Kaiho, Norihiko Tsuchiya, Takahiro Yoneyama, Narihiko Kakoi, Sadafumi Kawamura, Tatsuo Tochigi, Tomonori Habuchi, Chikara Ohyama, Yoichi Arai

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E686 - E687   2015年04月

研究発表要旨（国際会議）  

PREDICTIVE RISK FACTORS OF POST-TRANSPLANT HIGH-GRADE CMV REACTIVATION IN CMV-SEROPOSITIVE PATIENTS IN THE MODERN IMMUNOSUPPRESSIVE ERA

Mitsuru Saito, Shigeru Satoh, Hiroshi Tsuruta, Susumu Akihama, Takamitsu Inoue, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E1068 - E1068   2015年04月

研究発表要旨（国際会議）  

PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TREATED BY INTERMITTENT CHEMOTHERAPY WITH DOCETAXEL AND PREDNISOLONE

Shintaro Narita, Takuya Koie, Shigeyuki Yamada, Kazuhiko Orikasa, Shigeki Matsuo, Hiroshi Aoki, Shigeto Ishidoya, Senji Hoshi, Norihiko Tsuchiya, Chikara Ohyama, Yoichi Arai, Tomonori Habuchi

JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC )  193 ( 4 ) E1086 - E1087   2015年04月

研究発表要旨（国際会議）  

血清3分岐、4分岐N型糖鎖は去勢抵抗性前立腺癌予測マーカーとなりえる

米山 徹, 石橋 祐介, 飛澤 悠葵, 畠山 真吾, 成田 伸太郎, 古家 琢也, 羽渕 友則, 大山 力

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  103回   493 - 493   2015年04月

高脂肪食摂取によるマウス前立腺癌xenograftの腫瘍増大とリン脂質代謝の変化

小泉 淳, 黄 明国, 中西 広樹, 秋濱 晋, 沼倉 一幸, 鶴田 大, 齋藤 満, 井上 高光, 成田 伸太郎, 土谷 順彦, 佐藤 滋, 佐々木 雄彦, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  103回   594 - 594   2015年04月

マウス去勢抵抗性前立腺癌骨転移モデルにおける去勢による骨密度低下と骨転移促進効果

高山 孝一朗, 井上 高光, 成田 伸太郎, 黄 明国, 鶴田 大, 秋濱 晋, 齋藤 満, 土谷 順彦, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  103回   527 - 527   2015年04月

分子標的薬時代における1st-Lineインターフェロン単独療法適応の検討

井上 高光, 土谷 順彦, 鶴田 大, 秋濱 晋, 齋藤 満, 成田 伸太郎, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  103回   775 - 775   2015年04月

局所進行腎盂尿管癌に対する補助化学療法の意義 腎機能低下症例における薬剤選択

成田 伸太郎, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  103回   389 - 389   2015年04月

腎癌と肥満およびアディポネクチンシグナルの関連検討

成田 伸太郎, 伊藤 隆一, 鶴田 大, 秋濱 晋, 齋藤 満, 井上 高光, 土谷 順彦, 佐藤 滋, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  103回   643 - 643   2015年04月

腎細胞癌進展とインスリンレセプター発現との逆関連 臨床およびマウス実験での検討

高橋 誠, 井上 高光, 黄 明国, 鶴田 大, 秋濱 晋, 齋藤 満, 成田 伸太郎, 土谷 順彦, 佐藤 滋, 羽渕 友則

日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  103回   594 - 594   2015年04月